Weekly Recap: Q2 revenue up 22% and NCCN mentions clonoSEQ

Adaptive Biotechnologies Corp. (NASDAQ:ADPT) posted Q2 2026 revenue of $72M, up 22% YoY with core MRD revenue rising 33%, and the NCCN guideline now citing clonoSEQ for blood MRD in multiple myeloma could accelerate clinical adoption and revenue growth.Previous Week RecapThis is an AI-generated sum…